Zentalis Pharmaceuticals

company

About

Zentalis is a pharmaceutical company focused on developing clinical therapeutics for cancer patients.

  • 101 - 250

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$25M
Industries
Biopharma,Biotechnology,Pharmaceutical
Founded date
Dec 1, 2014
Number Of Employee
101 - 250
Operating Status
Active

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer.

It was founded 2014 and headquartered in New York, United States.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$25M
Zentalis Pharmaceuticals has raised a total of $25M in funding over 2 rounds. Their latest funding was raised on Apr 27, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 27, 2022 Post-IPO Equity $25M 1 Pfizer Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Zentalis Pharmaceuticals is funded by 1 investors. Pfizer are the most recent investors.
Investor Name Lead Investor Funding Round
Pfizer Yes Post-IPO Equity